Choices aplenty: Antifungal prophylaxis in hematopoietic stem cell transplant recipients

Bone Marrow Transplantation

Volumn 34, Issue 5, 2004, Pages 377-389

  Hamza, N S ^a   Ghannoum, M A ^a   Lazarus, Hillard M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Allogeneic transplantation; Galactomannan; Invasive aspergillosis; Invasive fungal infection; Primary chemoprophylaxis

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DNA; FLUCONAZOLE; FLUDARABINE; FUNGUS ANTIGEN; INFLIXIMAB; ITRACONAZOLE; MICAFUNGIN; MICONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PLACEBO; POSACONAZOLE; PREDNISOLONE; RAPAMYCIN; RAVUCONAZOLE; RNA; TACROLIMUS; VORICONAZOLE;

ABDOMINAL PAIN; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; BODY FLUID; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CONSTIPATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; FATALITY; FATIGUE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER TOXICITY; MORTALITY; MOULD; MYCOSIS; NAUSEA; NEPHROTOXICITY; PATHOGENESIS; PHLEBITIS; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RECIPIENT; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SOMNOLENCE; VISUAL DISORDER; VOMITING; XEROSTOMIA;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 4544351985     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704603     Document Type: Short Survey

References (90)

1. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101: 3365-3372.
2. Wingard JR. Antifungal chemoprophylaxis after blood and marrow transplantation. Clin Infect Dis 2002; 34: 1386-1390.
3. Martino R, Subira M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475-482.
4. Alexander BD. Diagnosis of fungal infection: new technologies for the mycology laboratory. Transpl Infect Dis 2002; 4 (Suppl. 3): 32-37.
5. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
6. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-316.
7. Jantunen E, Anttila VJ, Ruutu T. Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress? Bone Marrow Transplant 2002; 30: 925-929.
8. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-1324.
9. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
10. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571.
11. Baden LR. Prevention and therapy of fungal infections in bone marrow transplantation. Leukemia 2003; 17: 1038-1041.
12. Wingard JR, Merz WG, Rinaldi MG et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277.
13. Chandrasekar PH, Gatny CM. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. J Antimicrob Chemother 1994; 33: 309-318.
14. Abi-Said D, Anaissie E, Uzun O et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-1128.
15. Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multi-center trial. Ann Intern Med 1993; 118: 495-503.
16. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
17. Laverdiere M, Rotstein C, Bow EJ et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother 2000; 46: 1001-1008.
18. Kanda Y, Yamamoto R, Chizuka A et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611-1625.
19. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40: 3551-3557.
20. Steinbach WJ, Perfect JR. Newer antifungal therapy for emerging fungal pathogens. Int J Infect Dis 2003; 7: 5-20.
21. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151.
22. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37 (Suppl. 3): S157-S187.
23. Gotzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev 2002; 2: CD000026.
24. Bow EJ, Laverdiere M, Lussier N et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-3246.
25. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
26. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-2061.
27. Kern W, Behre G, Rudolf T et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998; 83: 291-301.
28. MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002; 112: 369-379.
29. Strahilevitz J, Sugar AM, Engelhard D. Fluconazole in transplant recipients: options and limitations. Transpl Infect Dis 2000; 2: 62-71.
30. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
31. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs 2001; 61 (Suppl. 1): 39-47.
32. Glasmacher A, Molitor E, Hahn C et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998; 12: 1338-1343.
33. Crippa F, Corey L, Leisenring W et al. Administration of itraconazole for antifungal prophylaxis in stem cell transplant recipients: levels and drug interactions. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000; (Abstr. 850).
34. Menichetti F, Del Favero A, Martino P et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28: 250-255.
35. Morgenstern GR, Prentice AG, Prentice HG et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105: 901-911.
36. Harousseau JL, Dekker AW, Stamatoullas-Bastard A et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44: 1887-1893.
37. Boogaerts M, Maertens J, van Hoof A et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 2001; 48: 97-103.
38. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-713.
39. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fuconazole for prevention of fungal infections in allogeneic stem cell transplant patients. Blood 2004; 103: 1527-1533.
40. Glasmacher A, Prentice A, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a metaanalysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-4626.
41. Perfect JR. New antifungal agents. Transpl Infect Dis 2002; 4 (Suppl. 3): 52-61.
42. Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-1559.
43. Wolff SN, Fay J, Stevens D et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000; 25: 853-859.
44. Schwartz S, Behre G, Heinemann V et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93: 3654-3661.
45. Tollemar J, Ringden O, Andersson S et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577-582.
46. Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163-168.
47. Mattiuzzi GN, Estey E, Raad I et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003; 97: 450-456.
48. Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev 1997; 10: 477-504.
49. Lass-Florl C, Gunsilius E, Gastl G et al. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol 2003; 82: 565-569.
50. Gupta AK, Tomas E. New antifungal agents. Dermatol Clin 2003; 21: 565-576.
51. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther 2003; 25: 1321-1381.
52. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637.
53. Lazarus HM, Blumer JL, Yanovich S et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42: 395-402.
54. Ghannoum MA, Kuhn DM. Voriconazole - better chances for patients with invasive mycoses. Eur J Med Res 2002; 7: 242-256.
55. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032-1037.
56. Courtney R, Pai S, Laughlin M et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47: 2788-2795.
57. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-1457.
58. Mattiuzzi G, Riehl T, Pierce S et al. Intravenous itraconazole (ITRA) versus caspofungin (CASPO) for prophylaxis of invasive fungal infections (IFI) in patients (PTS) with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC). 44th Annual Meeting of the American Society of Hematology, Philadelphia. Blood 2002; 100: 1286a.
59. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30.
60. Van Burik HJ, Ratantharatharthorn V, Lipton J et al. Randomized, double-blind trial of micafungin (MI) versus fluconazole (FL) for prophylaxis of invasive fungal infections in patients (pts) undergoing hematopoietic stem cell transplant (HSCT), NIAID/BAMSG Protocol 46. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2002; (Abstr. M-12381).
61. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
62. Sulahian A, Boutboul F, Ribaud P et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 2001; 91: 311-318.
63. Patterson TF, Miniter P, Patterson JE et al. Aspergillus antigen detection in the diagnosis of invasive aspergillosis. J Infect Dis 1995; 171: 1553-1558.
64. Boutboul F, Alberti C, Leblanc T et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34: 939-943.
65. Bennett JE, Kauffman C, Walsh T et al. Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups. Clin Infect Dis 2003; 36: S123-7.
66. Herbrecht R, Letscher-Bru V, Oprea C et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898-1906.
67. Ulusakarya A, Chachaty E, Vantelon JM et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000; 1: 111-116.
68. Pinel C, Fricker-Hidalgo H, Lebeau B et al. Detection of circulating Aspergillus fumigatus galactomannan: Value and limits of the Platelia Test for diagnosing invasive aspergillosis. J Clin Microbiol 2003; 41: 2184-2186.
69. Stevens DA. Diagnosis of fungal infections: current status. J Antimicrob Chemother 2002; 49 (Suppl. 1): 11-19.
70. Hebart H, Loffler J, Meisner C et al. Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000; 181: 1713-1719.
71. Einsele H, Quabeck K, Muller KD et al. Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation. Lancet 1998; 352: 1443.
72. Sanguinetti M, Posteraro B, Pagano L et al. Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2003; 41: 3922-3925.
73. Abbas J, Bodey GP, Hanna HA et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 2000; 160: 2659-2664.
74. Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clin North Am 2002; 16: 915-933.
75. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954-958.
76. Menichetti F, Del Favero A, Martino P et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med 1994; 120: 913-918.
77. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995; 172: 1035-1041.
78. Rotstein C, Bow EJ, Laverdiere M et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331-340.
79. Koh LP, Kurup A, Goh YT et al. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002; 71: 260-267.
80. Huijgens PC, Simoons-Smit AM, van Locnen AC et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 1999; 52: 376-380.
81. Nucci M, Biasoli I, Akiti T et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 30: 300-305.
82. Riley DK, Pavia AT, Beatty PG et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97: 509-514.
83. Timmers GJ, Zweegman S, Simoons-Smit AM et al. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 2000; 25: 879-884.
84. Neely MN, Ghannoum MA. The exciting future of antifungal therapy. Eur J Clin Microbiol Infect Dis 2000; 19: 897-914.
85. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
86. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
87. Shepherd DB, White RJ, Weston IE, Henke T. Anidulafungin: a phase 1 study to identify the maximum tolerated dose in healthy volunteers. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. 2001; (Abstr. A-36).
88. Maertens J, Van Eldere J, Verhaegen J et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transpla nt recipients. J Infect Dis 2002; 186: 1297-1306.
89. Maertens J, Verhaegen J, Lagrou K et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-1610.
90. Becker MJ, Lugtenburg EJ, Cornelissen JJ et al. Galactomannan detection in computerized tomography-based bronchoalveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121: 448-457.